Nitazoxanide

Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule 1 Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFIT GENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout and recommended Phase 2 doses remain on track for 1H26 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 12, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the strong commercial performance of Iqirvo® in its first full year on the primary biliary cholangitis (PBC) market has triggered a US$20M milestone payment from Ipsen under the companies’ licensing agreement. The commercial success of Iqirvo® in 2025 underscores the strength of our partnership with Ipsen and exceeded our initial expectations with first-year net sales reaching US$208M. This performance activated a US$20M milestone payment ahead of plan, reinforcing GENFIT’s financial position. This momentum also led to the receipt of an additional €30M tranche under GENFIT’s royalty‑financing agreement with HCRx, enhancing financial flexibility in a non-dilutive way. In parallel, Ipsen confirmed the initiation of the first and only global Phase 3 clinical trial in primary sclerosing cholangitis (PSC), addressing a significant unmet medical need, as no approved therapies currently exist for this severe and progressive disease. PSC represents a substantial untapped market opportunity, comparable in size to second line PBC. Should Iqirvo® ultimately receive regulatory approval for this indication, GENFIT would be eligible for additional milestone payments as well as additional double‑digit royalties. Beyond Iqirvo®, GENFIT continues to advance its oncology program. The ongoing Phase 1b study in cholangiocarcinoma (CCA), evaluating GNS561 in combination with a MEK inhibitor, is progressing in line with expectations. As communicated in December 2025, early positive activity was observed in the first evaluable patients at Week 6. Enrollment for a the next escalated-dose cohort has now been completed, with no dose-limiting toxicities (DLTs) reported to date. Recruitment for the following one will now proceed, consistent with the predefined dose‑escalation process. Multi-cohort readouts on safety, tolerability and activity along with the determination of the recommended Phase 2 doses remain expected by the end of the first half of 2026. Pascal Prigent, CEO of GENFIT declared: “We are pleased with Ipsen’s continued success with Iqirvo®. Net sales have surpassed US$200M in 2025 and this remarkable performance has allowed us to get the first commercial milestone a year earlier than anticipated. We believe that this commercial trajectory has the potential to be transformative for our business model. We are also pleased with the progress of our GNS561 program, with a new cohort fully recruited. This program might bring significant hope for patients with a devastating disease, and we are eagerly awaiting new data. As we are also anticipating the first ACLF patients to be included in a phase 2 evaluating G1090N in the second half of the year we believe 2026 will be a landmark year for GENFIT.” GENFIT will publish its 4Q25 revenue and cash position on February 26, 2026. All details from Ipsen’s communication are available here: END ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries. 2 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements about the future commercial trajectory of Iqirvo® in PBC, the ability to obtain marketing authorization for elafibranor in PSC, the potential to receive future milestone payments and royalties under the Ipsen agreement, the timing, progression and expected data readouts of GENFIT’s ongoing clinical programs such as the Phase 1b study in cholangiocarcinoma and the planned Phase 2 study of G1090N in ACLF, and more generally GENFIT’s expectations regarding its financial position, strategic outlook and prospects for 2026 and beyond. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( ) and the AMF's website ( ), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC, including the Half-Year Business and Financial Report at June 30, 2025, or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACTS GENFIT | Investors Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 | jean-christophe.marcoux@genfit.com GENFIT | Media Bruno Arabian – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Based on contractual change rates (€76,6M sales in 4Q25 and €184M annual sales in 2025) 2 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo® . Attachment GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales

点击上面蓝字 关注我们 编者按        康为世纪医学检验事业部自2023年9月24日开始，每周以Helicobacter pylori 为检索词查阅PubMed中的相关文献，对每周的幽门螺杆菌相关英文文献进行汇总梳理，整理成中英文对照标题，中文结论，便于随时了解相关研究方向。截至2026年1月19日，已整理至115期，每周一持续更新，希望对从事幽门螺杆菌科研的朋友们有所帮助。 数据库：PubMed      检索关键词：Helicobacter pylori            检索时间：2026年1月19日    检索结果：Hp 英文论文55164 篇，其中本期新增有效文献 33 篇，详见下表1。 一、整体研究趋势    本期文献整体呈现“以临床需求为核心，兼顾基础机制与技术创新”的研究趋势，既围绕Hp根除治疗方案优化、疾病关联风险、临床诊断改进等实际问题展开，也深入探索致病分子机制及新型治疗物质研发，为Hp感染的精准防控、规范治疗及科学研究提供了全面支撑。 二、主要研究方向 1 Hp根除治疗方案优化    聚焦不同方案的疗效与适用场景，左氧氟沙星序贯疗法在克拉霉素耐药高发区更优，特戈拉赞三联疗法可作为一线选择，硝唑尼特三联疗法根除率优于标准三联，二联疗法依从性高，复方益生菌联合三联疗法耐受性更佳（文献 1、4、16、19、23）。 2 Hp与多系统疾病关联及风险因素   Hp 感染是中国胃癌主要风险因素（占病例 3/4），根除治疗 10 年以上患者中开放性萎缩和重度肠上皮化生是胃癌独立危险因素；同时与慢性萎缩性胃炎、缺铁相关，还可能参与帕金森病发病（文献 2、5、12、14、24、33）。 3  诊断技术创新与生物标志物探索     研发出超灵敏 Hp 光纤生物传感器（检测限 1.37 CFU/mL）；吉姆萨染色诊断性能优异，H&E 与吉姆萨组合可提升检测效率；儿童 NLR/PLR、血清 C 反应蛋白 / 白蛋白比值可作为感染相关标志物，Hp 感染会影响 AI 辅助内镜检测效果（文献 15、21、25、26、29）。 4  致病分子与表观遗传机制     Hp 感染可诱导细胞特异性表观遗传改变，ELMO1 甲基化与 Med31 相互作用通过 M2 极化促进胃癌 EMT 及肠化生；其对肠道和肿瘤内微生物组的影响可能关联胃肠癌免疫治疗疗效（文献 3、8、11、17、24、27、30）。 5  天然物质与新型靶向药物研发      靛蓝与靛红纳米颗粒经封装后抗 Hp 活性提升，牛油果种子水提物可辅助抑制 Hp，新型三唑席夫碱杂合物能双重抑制脲酶和 α- 葡萄糖苷酶，小麦胚芽提取物可调节 Hp 相关宿主通路（文献 22、30、31、32）。 6  临床指南与防控策略完善       制定 Hp 筛查、诊断及转诊共识算法，建议症状持续≥2 周患者先经抗体初筛再确证；临床实践与循证指南存在差距，《欧洲抗癌法典》第五版将 Hp 检测与治疗纳入抗癌干预（文献 6、7、28）。 三、本期新增文献详细列表  表1   新增的33篇Hp英文论文信息汇总表 1 Title Yang C, Cheng J, Zhang M, et al. Beneficial Effects of a Compound Probiotic in Helicobacter pylori-Infected Patients Aged Over 40 Years: An Open-Label Randomized Clinical Trial. Int J Antimicrob Agents. Published online January 9, 2026. doi:10.1016/j.ijantimicag.2026.107712  IF: 4.6 标题 复方益生菌对40岁以上幽门螺杆菌感染患者的益处：一项开放标签随机临床试验 结论 虽然三联疗法联合益生菌（TTP，益生菌、阿莫西林、克拉霉素和埃索美拉唑）在根除效果上不如四联铋剂疗法（BQT，枸橼酸铋钾、阿莫西林、克拉霉素和埃索美拉唑），但其耐受性和对肠道微生物群失调的保护作用更好。在年龄≥40岁的患者中，TTP达到了非劣效性根除率，表明该亚组可能需要进一步研究。 备注 南方医科大学深圳医院胃肠病科。 2 Title Lee HT, Lee AY, Hong H, et al. Endoscopic predictors of iron deficiency in Helicobacter pylori gastritis: a Kyoto classification-based study. Clin Endosc. Published online November 6, 2025. doi:10.5946/ce.2025.175  IF: 2.3 标题 幽门螺杆菌胃炎患者缺铁的内镜预测因素：基于京都分类的研究 结论 幽门螺杆菌胃炎患者年龄较小、女性、增生性息肉较大（≥5 毫米）与缺铁有关。这些特征可能有助于识别缺铁风险较高的患者。 备注 - 3 Title Vlasac I, Christensen BC, Salas LA. Normal gastric tissue Helicobacter pylori infection is associated with tissue cell composition, and cell type-specific epigenetic age acceleration, mitotic tick rate, and repetitive element methylation alterations. Epigenet Rep. 2025;3(1):10.1080/28361512.2025.2554836. doi:10.1080/28361512.2025.2554836 标题 正常胃组织幽门螺杆菌感染与组织细胞组成、细胞类型特异性表观遗传学年龄加速、有丝分裂节律以及重复元件甲基化改变相关 结论 幽门螺杆菌感染会诱导持久的、细胞特异性的表观遗传学改变，这种改变可能会通过细胞通路的改变、基因组的不稳定性和持续的炎症促进炎症和致癌胃微环境的形成。 备注 - 4 Title Naeem M, Hussain M. Retrospective Comparison of Conventional Triple Therapy and Levofloxacin-Based Sequential Therapy for Helicobacter pylori Eradication in Mardan Medical Complex. Cureus. 2025;17(12):e98803. doi:10.7759/cureus.98803  IF: 1.3 标题 马尔丹医疗中心幽门螺杆菌根除治疗中常规三联疗法与左氧氟沙星序贯疗法的回顾性比较 结论 序贯疗法获得了更高的清除率，在克拉霉素耐药高发地区应作为首选方案。 备注 - 5 Title Wang Y, Liu Z, Li W, et al. Gastric cancer in China: Epidemiology, risk factors, and screening. Chin J Cancer Res. 2025;37(6):937-948. doi:10.21147/j.issn.1000-9604.2025.06.06  IF: 6.3 标题 中国胃癌：流行病学、风险因素及筛查 结论 中国胃癌的发病率和死亡率存在明显的人口和地域差异，男性、老年人和农村居民的发病率较高。幽门螺杆菌感染是主要的风险因素，约占中国胃癌病例的四分之三。高危地区开展的大规模随机对照干预试验，为根除幽门螺杆菌是有效的一级预防策略提供了有力证据。其他已确定的风险因素包括高盐饮食和新鲜水果和蔬菜摄入不足。一些国家在高危人群中开展内窥镜筛查的二级预防，被证明在早期发现和降低死亡率方面是有效的。但中国的胃癌防控工作仍面临着巨大的挑战，包括抗生素耐药性不断增加、筛查覆盖面有限以及医疗资源的地区差异。 备注 北京大学肿瘤医院流行病学研究室。 6 Title Abere S, Sixtus O, Koko-James N. Establishing a Consensus Algorithm for H. Pylori Screening, Diagnosis, Initial Management, and Referral Protocols for Primary Care Physicians. Niger Med J. 2025;66(4):1374-1385. doi:10.71480/nmj.v66i4.789 标题 建立针对幽门螺杆菌筛查、诊断、初始管理及初级保健医师转诊方案的共识算法 结论 所提出的算法为初级和二级医疗保健机构的医生选择最有效的幽门螺杆菌感染治疗方案提供了全面指导。幽门螺杆菌抗体检测是一种初筛工具，适用于症状持续存在或持续时间超过两周的患者，建议进行阳性确证检测。 备注 - 7 Title Gatta L, Scarpignato C, Zullo A, et al. Empirical first- and second-line eradication regimens for Helicobacter pylori adult-infected patients: a National Survey among Italian gastroenterologists and general practitioners. Eur J Gastroenterol Hepatol. Published online December 15, 2025. doi:10.1097/MEG.0000000000003111  IF: 1.8 标题 针对幽门螺杆菌成人感染患者的经验性一线和二线根除方案：意大利胃肠病学家与全科医生全国调查 结论 经验性治疗方案选择、质子泵抑制剂剂量和益生菌的使用经常与指南建议不一致。这些发现强调需要使临床实践与循证标准保持一致，以提高根除率、优化成本效益和保护医疗资源。 备注 - 8 Title Rajaei A, Mahdavi P, Chimehrad R, Zakeri M, Sadeghloo Z, Mojarad EN. A vicious cycle inducer in gastric pathogenesis: implication of Helicobacter pylori. Arch Microbiol. 2026;208(2):122. doi:10.1007/s00203-025-04662-z  IF: 2.6 标题 胃部发病机制中的恶性循环诱导因子：幽门螺杆菌的影响 结论 通过阐明毒力因子、DNA损伤反应缺陷和免疫调节之间的协同相互作用，本综述重点探讨了可能有助于阻断持续性感染并最终降低幽门螺杆菌相关性胃癌风险的潜在干预节点。 备注 - 9 Title Okada T, Awasthi SP, Hinenoya A, et al. Streptococcus mobilis sp. nov., isolated from a Helicobacter pylori-positive pre-neoplastic human stomach. Int J Syst Evol Microbiol. 2026;76(1):10.1099/ijsem.0.007016. doi:10.1099/ijsem.0.007016  IF: 2.0 标题 从幽门螺杆菌阳性的癌前病变患者的胃组织中分离出的可动链球菌新种（Streptococcus mobilis sp. nov.） 结论 从一名幽门螺杆菌阳性、胃粘膜癌前病变的日本女性患者的胃中分离出了菌株MT/JULY 2010T。根据各种实验及系统进化分析的表型和基因型结果，菌株MT/JULY 2010T代表了链球菌属的一个新物种。 备注 - 10 Title Ueyama H, Yao T, Nakamura S, et al. Gastric epithelial neoplasms in Helicobacter pylori-uninfected patients. Digestion. Published online January 12, 2026. doi:10.1159/000550411  IF: 3.6 标题 幽门螺杆菌未感染患者的胃上皮肿瘤 结论 研究成果将未感染幽门螺杆菌的胃上皮肿瘤（不包括食管胃交界处腺癌和胃神经内分泌肿瘤）分为七个亚型。 备注 - 11 Title Jia K, Chen Y, Dai D, et al. Impact of Helicobacter pylori infection on gut and intratumoral microbiome and its association with immunotherapy response in gastrointestinal cancer. BMC Med. Published online January 12, 2026. doi:10.1186/s12916-025-04575-0  IF: 8.3 标题 幽门螺杆菌感染对肠道及肿瘤内微生物组的影响及其与胃肠癌免疫治疗反应的相关性 结论 幽门螺杆菌对肠道和肿瘤内微生物组的结构和功能活性有显著影响，其中一些可能会影响免疫疗法的疗效。在建立基于肠道微生物组的免疫疗法疗效预测模型时，应考虑幽门螺杆菌感染状态的临床价值。 备注 北京大学肿瘤医院胃肠肿瘤科。 12 Title Bang CS, Hasanuzzaman M, Lee JJ, Gong EJ. Association between Helicobacter pylori infection and Parkinson's disease: A systematic review and meta-analysis. Eur J Clin Invest. Published online January 12, 2026. doi:10.1111/eci.70164  IF: 3.6 标题 幽门螺杆菌感染与帕金森病的关联：系统回顾与荟萃分析 结论 研究结果支持幽门螺杆菌感染在帕金森病发病机制中的潜在作用，尽管无法确定因果关系。 备注 - 13 Title Kraja B, Burazeri G. Limitations of Helicobacter pylori-attributable gastric cancer estimates in Albania. Gastric Cancer. Published online January 13, 2026. doi:10.1007/s10120-025-01712-9  IF: 5.1 标题 阿尔巴尼亚可归因于幽门螺杆菌的胃癌估计值的局限性 结论 无 备注 - 14 Title Zhang Y, Feng Y, You C, Zhang L. Relationship between Helicobacter pylori infection and different pathological types of chronic atrophic gastritis and analysis of serum gastric function. J Infect Dev Ctries. 2025;19(12):1774-1779. doi:10.3855/jidc.21486  IF: 1.2 标题 幽门螺杆菌感染与慢性萎缩性胃炎不同病理类型的关系及血清胃功能分析 结论 幽门螺杆菌感染与慢性萎缩性胃炎密切相关，不同病理类型和显微镜下的幽门螺杆菌感染率和血清胃功能存在明显差异。结合血清胃功能和幽门螺杆菌检测有助于评估萎缩的范围和严重程度。 备注 首都医科大学附属北京积水潭医院健康管理中心。 15 Title Elsaadany E, El Amrousy D, Qassem SS, et al. Platelets/lymphocytes ratio and neutrophils/lymphocytes ratio in children with H. pylori associated gastritis: a canary in the mine?. Pediatr Res. Published online January 13, 2026. doi:10.1038/s41390-025-04727-1  IF: 3.1 标题 幽门螺杆菌相关性胃炎患儿的血小板/淋巴细胞比值与中性粒细胞/淋巴细胞比值：潜在预警指标的探索？ 结论 幽门螺杆菌阳性患者的中性粒细胞/淋巴细胞比值（NLR）和血小板/淋巴细胞比值（PLR）显著升高。此外，在有上消化道症状的儿童中，PLR和NLR是幽门螺杆菌感染存在和严重程度的良好预测指标。 备注 - 16 Title Park JY, Hong SJ, Choi IJ, et al. Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial. Helicobacter. 2026;31(1):e70106. doi:10.1111/hel.70106  IF: 4.3 标题 基于特戈拉赞的三联疗法根除幽门螺杆菌：一项III期多中心随机临床试验 结论 以特戈拉赞为基础的三联疗法（50毫克和100毫克剂量）并不比以兰索拉唑为基础的疗法效果差，而且耐受性良好。表明基于特戈拉赞的三联疗法是根除幽门螺杆菌的可行一线选择。 备注 - 17 Title Merola E, Pes GM, Graham DY, Dore MP. Helicobacter pylori and Cancer: What's the Link?. Clin Exp Gastroenterol. 2026;19:1-11. Published 2026 Jan 7. doi:10.2147/CEG.S495588  IF: 2.3 标题 幽门螺杆菌与癌症：关联机制是什么？ 结论 综合了分子见解、流行病学趋势和临床数据，探讨了幽门螺杆菌导致胃癌发生的多方面途径，整合了目前有关微生物毒力、宿主信号干扰、免疫调节和表观遗传重塑的知识。 备注 - 18 Title Satoh T. Beyond Helicobacter pylori Eradication: Endoscopic Surveillance of the Post-Eradication Stomach. Dig Endosc. 2026;38(1):e70101. doi:10.1111/den.70101  IF: 4.7 标题 超越幽门螺杆菌根除：根除后胃部的内窥镜监测 结论 无 备注 - 19 Title Ali SH, Shaikh UA, Shahzad A, et al. Comparative Efficacy and Safety of Nitazoxanide-based Triple Therapy Versus Standard Triple Therapy in Treating Helicobacter Pylori Infections: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. J Clin Gastroenterol. Published online January 15, 2026. doi:10.1097/MCG.0000000000002328  IF: 2.8 标题 基于硝唑尼特三联疗法与标准三联疗法治疗幽门螺杆菌感染的疗效和安全性比较：随机对照试验的最新系统回顾与荟萃分析 结论 与标准三联疗法相比，基于硝唑尼特的疗法在主要结果（包括幽门螺杆菌根除率）方面有明显改善。在次要结果中，以硝唑尼特为基础的治疗显示腹痛和恶心无显著减轻。未来的研究应关注硝唑尼特的最佳持续时间、耐药性模式、安全性和症状缓解。 备注 - 20 Title Kountouras J, Zavos C, Polyzos SA, et al. Potential Influence of Helicobacter Pylori on Glaucoma-Related Alterations of Ocular Surface Microbiota and Dry Eye Disease Pathophysiology. Invest Ophthalmol Vis Sci. 2025;66(15):72. doi:10.1167/iovs.66.15.72  IF: 4.7 标题 幽门螺杆菌对青光眼相关眼表微生物群改变及干眼症病理生理学的潜在影响 结论 无 备注 - 21 Title Zhang J, Gou L, Gao Z, et al. Self-assembled 3D/0D quasi-core-shell sensitized optical fiber biosensor for ultrasensitive detection of Helicobacter pylori. Biosens Bioelectron. Published online January 6, 2026. doi:10.1016/j.bios.2026.118375  IF: 10.5 标题 用于超灵敏检测幽门螺杆菌的自组装3D/0D准核壳敏化光纤生物传感器 结论 提出了一种利用3D/0D准核壳材料提高光纤生物传感器性能的新策略，有助于快速、高灵敏度的目标检测，在微生物诊断方面大有可为。设计出一种用于超灵敏幽门螺杆菌检测的光纤生物传感器，灵敏度为1.465 nm-（lg CFU/mL）-1，响应时间为16秒，检测限为1.37 CFU/mL。 备注 兰州大学物理科学与技术学院。 22 Title Lin F, Chen M, Li Y, et al. Edible packaging fucoidan/ovalbumin encapsulation co-delivery of indigo and Indirubin nanoparticles: Preparation, characterization, and preliminary mechanism of action against Helicobacter pylori in vitro. Int J Biol Macromol. Published online January 12, 2026. doi:10.1016/j.ijbiomac.2026.150104  IF: 8.5 标题 可食用包装褐藻多糖/卵清蛋白包封靛蓝与靛红纳米颗粒的共递送：制备、表征及体外抗幽门螺杆菌作用机制初步研究 结论 靛蓝和靛红素具有显著的抗幽门螺杆菌活性，将它们封装在卵清蛋白/褐藻糖胶自组装纳米颗粒中可显著提高溶解度和抗幽门螺杆菌的功效。这种方法为开发针对幽门螺杆菌感染的新型天然疗法提供了实验基础。 备注 天津中医药大学研究生院。 23 Title Taufiqqurrachman I, Syam AF, Maulahela H, et al. Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens for Helicobacter pylori eradication: a systematic review and network meta-analysis. BMJ Open Gastroenterol. 2026;13(1):e002037. doi:10.1136/bmjgast-2025-002037  IF: 2.9 标题 二联、三联和四联疗法作为根除幽门螺杆菌一线治疗方案的疗效、安全性和依从性比较：一项系统回顾与网络荟萃分析 结论 二联疗法是一种很有前景的一线治疗方案，其疗效和不良事件发生率相当，依从性更高，但三联疗法在网络荟萃分析中成为最有效一线治疗方案的概率最高，其次是四联疗法。要完善全球根除策略，还需要在非亚洲人群中开展进一步研究，并采用抗药性指导治疗方法。 备注 - 24 Title Lu T, Yu T, He C, et al. Interaction between ELMO1 DNA methylation and Med31 promotes H. pylori-induced gastric cancer EMT and intestinal metaplasia via M2 polarization. Sci Rep. Published online January 14, 2026. doi:10.1038/s41598-026-35314-x  IF: 3.9 标题 ELMO1 DNA甲基化与Med31之间的相互作用通过M2极化促进幽门螺杆菌诱导的胃癌上皮-间质转化（EMT）及肠化生 结论 ELMO1甲基化与Med31相互作用，激活M2巨噬细胞极化，从而促进幽门螺杆菌感染的胃癌的上皮-间质转化及肠化生。 备注 南方科技大学医院胃肠科。 25 Title Yan L, Zhang L, Luo R, et al. Effect of Helicobacter pylori infection on deep learning-assisted detection of gastric neoplastic lesions under white light endoscopy. Surg Endosc. Published online January 14, 2026. doi:10.1007/s00464-025-12560-0  IF: 2.7 标题 幽门螺杆菌感染对白光内镜下深度学习辅助检测胃肿瘤性病变的影响 结论 该人工智能（AI）系统在胃肿瘤检测方面表现出色，而幽门螺杆菌感染会显著影响其检测效果（尤其是对于非肿瘤性病变和低级别异型增生）。根除幽门螺杆菌似乎能恢复AI系统的诊断性能。在静止图像分类方面，其诊断准确率与专业内镜医师相当，且优于非专业人士，这表明其有潜力成为临床内镜的辅助工具。 备注 - 26 Title Alwahaibi N, Al Mamari AM, Al Aamri A, et al. Assessing the diagnostic accuracy of routine hematoxylin and eosin, Alcian Blue/Periodic Acid-Schiff, and Giemsa stains in the detection of Helicobacter pylori in gastric biopsies. F1000Res. 2026;14:1148. doi:10.12688/f1000research.170290.2 标题 评估常规苏木精-伊红、阿尔新蓝/过碘酸及吉姆萨染色在胃活检幽门螺杆菌检测中的诊断准确性 结论 苏木精-伊红（H&E）表现出初步筛查的潜力，但其有限的灵敏度阻碍了最终诊断。阿尔新蓝/过碘酸（AB/PAS）被证明效率和经济性较低。吉姆萨染色保持了优异的诊断性能。本研究提供了比较方法学评估，表明H&E和吉姆萨染色组合可以提高检测效率和准确性。在临床实施之前还需进一步前瞻性验证。 备注 - 27 Title Snow JA, Hatzios SK, Salama NR. Managing dangerous liaisons: lessons from Helicobacter pylori for understanding bacterial carcinogenesis. J Bacteriol. Published online January 15, 2026. doi:10.1128/jb.00457-25  IF: 3.0 标题 危险相互作用的管理：从幽门螺杆菌中吸取教训，了解细菌致癌机制 结论 详细介绍了幽门螺杆菌的开创性发现及其后续工作，巩固了其作为微生物致癌物的地位。由于幽门螺杆菌感染的长期性以及宿主环境的相关重塑反过来促进了癌症的发生，幽门螺杆菌成为理解人类其他慢性细菌感染和病原体相关恶性肿瘤的模型生物。 备注 - 28 Title Alberts CJ, Bloem P, de Sanjosé S, et al. European Code Against Cancer, 5th edition - cancer-causing infections and related interventions. Mol Oncol. 2026;20(1):96-116. doi:10.1002/1878-0261.70172  IF: 4.5 标题 欧洲抗癌法典第5版——致癌性感染及相关干预措施 结论 最近出版的《欧洲抗癌法典》第五版建议：（1）按照本国推荐的年龄，为男孩和女孩接种乙肝病毒和人乳头瘤病毒疫苗；（2）按照本国的建议，参加乙肝病毒、丙肝病毒、艾滋病病毒和幽门螺杆菌的检测和治疗。 备注 - 29 Title Eser U, Özkan Z, Karabayir N. Can Serum C-Reactive Protein/Albumin Ratio be Used as a Marker of Chronic Helicobacter Pylori Infection?. Clin Lab. 2026;72(1):10.7754/Clin.Lab.2025.250113. doi:10.7754/Clin.Lab.2025.250113  IF: 0.6 标题 血清C反应蛋白/白蛋白比值能否作为慢性幽门螺杆菌感染的标志物？ 结论 C反应蛋白/白蛋白比值可能作为一种有价值的生物标志物，用于确认幽门螺杆菌感染的存在并反映患者的全身炎症状态。 备注 - 30 Title Tsai PL, Yeh YT, Yu TJ, et al. Gramineae Wheat Germ Extract Ameliorates Methylglyoxal-Induced Neurobehavioral Deficits Through Modulation of the Gut Microbiota and Tryptophan Metabolism. Mol Nutr Food Res. 2026;70(1):e70383. doi:10.1002/mnfr.70383  IF: 4.2 标题 禾本科小麦胚芽提取物通过调节肠道菌群和色氨酸代谢改善甲基乙二醛诱导的神经行为缺陷 结论 这些发现表明小麦胚芽提取物可能通过调节肠道微生物群组成和色氨酸代谢发挥神经保护作用，为预防神经退行性疾病的肠-脑轴靶向策略提供了新见解。 其中小麦胚芽提取物调节与幽门螺杆菌感染相关的细胞运动和上皮信号传导相关的宿主功能通路。 备注 - 31 Title Sultan A, Akhtar MN, Khalil AA, et al. Characterization of avocado seeds aqueous extract and its therapeutic effects on gastric ulcer. Nutr Metab (Lond). Published online January 16, 2026. doi:10.1186/s12986-026-01080-w  IF: 4.1 标题 鳄梨（牛油果）种子水提物的特性及其对胃溃疡的治疗作用 结论 用牛油果种子水提取物干预组与常规治疗相结合表现出积极效果（包括对幽门螺杆菌抑制），表明其作为胃溃疡治疗的天然辅助疗法的潜力。 备注 - 32 Title Gültekin E, Atalay A, Şirin Y. Design, synthesis, and combined computational and experimental evaluation of novel 1,2,4-triazole Schiff base hybrids as potent dual inhibitors of urease and α-glucosidase. Future Med Chem. Published online January 18, 2026. doi:10.1080/17568919.2026.2617604  IF: 3.4 标题 新型1,2,4-三唑席夫碱杂合物的设计、合成及其计算与实验联合评估：作为尿素酶和 α -葡萄糖苷酶的强效双重抑制剂 结论 通过整合光谱学、量子化学表征、酶活性测定和分子对接技术，本研究确定5a，尤其是5b，为具有双重脲酶和α-葡萄糖苷酶抑制作用的多功能支架，对幽门螺杆菌相关的胃病和2型糖尿病具有潜在应用价值。 备注 - 33 Title Onodera S, Sue S, Kaneko H, et al. Risk factors for gastric cancer diagnosed more than 10 years after eradication therapy of Helicobacter pylori. Scand J Gastroenterol. Published online January 18, 2026. doi:10.1080/00365521.2026.2615406  IF: 1.7 标题 幽门螺杆菌根除治疗超过10年后确诊胃癌的危险因素 结论 证实在幽门螺杆菌根除治疗10年以上的患者中，开放性萎缩和重度肠上皮化生是胃癌的独立危险因素。 备注 - 注：IF，影响因子（Impact factor，IF）。 编辑：李明； 校对 ：George 博士。